PDS Biotechnology Corp
NASDAQ:PDSB
PDS Biotechnology Corp
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Florham Park, New Jersey and currently employs 22 full-time employees. The company went IPO on 2015-10-01. The firm is engaged in the developing a pipeline of molecularly targeted immunotherapies. The firm owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. The company develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Florham Park, New Jersey and currently employs 22 full-time employees. The company went IPO on 2015-10-01. The firm is engaged in the developing a pipeline of molecularly targeted immunotherapies. The firm owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. The company develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.
Clinical Progress: PDS Biotech completed its VERSATILE-002 Phase II trial with strong survival and progression-free survival results in HPV16-positive head and neck cancer.
Trial Design Change: The company is seeking FDA approval to amend its ongoing Phase III VERSATILE-003 trial to include progression-free survival (PFS) as a surrogate primary endpoint, aiming to potentially accelerate regulatory submission.
Financial Results: Net loss narrowed to $9 million for Q3 2025, down from $10.7 million in the prior year, driven by reduced operating expenses.
Cash Position: Ended Q3 2025 with $26.2 million in cash; completed a $5.3 million equity raise after quarter-end.
Pipeline Updates: The National Cancer Institute presented new data validating PDS Biotech’s immunotherapy platforms, and the PDS01ADC colorectal trial advanced to Stage 2.
Market Context: Management emphasized the growing prevalence of HPV16-positive head and neck cancer and sees limited competition in this space.
